Europe ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)
The Europe ECMO market is expected to grow from US$ 141.83 million in 2022 to US$ 166.97 million by 2028. It is estimated to record a CAGR of 2.8% from 2022 to 2028.
Rising Prevalence of Cardiovascular Diseases and Respiratory Failures Drives Europe ECMO Market
Extracorporeal membrane oxygenation (ECMO) is a heart–lungs bypass machine.ECMO equipment is used in the treatment of cardiovascular diseases and respiratory failures.
Millions of deaths due to cardiovascular diseases (CVDs) are recorded every year across Europe.CVDs majorly cause mortality and morbidity in Europe, accounting for 45% of deaths in the region and 37% in the European Union (EU).
Chronic obstructive pulmonary disease (COPD) causes obstruction in the airflow from the lungs, which can lead to respiratory failure.It is one of the life-threatening illnesses that cause millions of deaths across the region.
According to World Health Organization (WHO), in 2022, COPD was the third leading cause of death. About 90% of COPD deaths occur in low- and middle-income countries. Therefore, the growing prevalence of cardiovascular diseases and respiratory failures drives the growth of the Europe ECMO market .
Europe ECMO Market Overview
The Europe ECMO market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe.Germany dominated the market in 2022.
Heart attack is the most serious consequence of coronary heart disease (CHD). More than 3.6 million people suffer from CHD, and more than 1.3 million have survived a stroke. The prevalence of CHD is rising in Germany. According to the latest WHO data published in 2020, Germany recorded 147,055 CHD deaths, or 20.98% of total deaths. Moreover, chronic obstructive pulmonary disease (COPD) has a high prevalence rate in Germany, and a further increase is expected in the coming years. In 2020, the number of isolated heart transplantations increased to 340, a rise of 2.1% compared with the previous year. However, the isolated lung transplantations amounted to 291, a decrease of 6.4%. The use of ECMO is still increasing, and a substantial proportion of hospitals perform very few ECMO runs. Small hospitals had significantly higher mortality, but dependence on hospital size and ECMO mortality was irregular. VV-ECMO was used for patients affected by COVID-19-related respiratory failure. The applications of extracorporeal circulation for mechanical support in cardiac and circulatory failure, which are referred to as extracorporeal life support (ECLS) or veno-arterial extracorporeal membrane oxygenation (VA-ECMO), have dramatically increased over the past decade in Germany from <300 cases in 2010 to 2,852 in 2020. During COVID-19 outbreak, in-hospital mortality in Germany was 68%. This is markedly higher than that reported by other countries or international registries. Thus, the above factors are expected to bolster the ECMO market during the forecast period.
Europe ECMO Market Revenue and Forecast to 2028 (US$ Million)
Europe ECMO Market Segmentation
The Europe ECMO market is segmented based on modality, application, age group, and country.
Based on modality, the Europe ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.
Based on application, the Europe ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.
Based on age group, the Europe ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.
Based on country, the Europe ECMO market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany dominated the market in 2022.
ABIOMED Inc, Braile Biomedica, Eurosets S.R.L., Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the Europe ECMO market.